Ruvalcaba-myhre-smith syndromeQ85.9

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Bannayan Syndrome; Bannayan-Zonana Syndrome; BRRS; Cowden/Bannayan-Riley-Ruvalcaba overlapping syndrome; Riley-Smith Syndrome; Ruvalcaba-Myhre Syndrome

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

HistoryThis section has been translated automatically.

Harris D. Riley and William R. Smith 1960; George A. Bannayan 1961.

EtiopathogenesisThis section has been translated automatically.

There is evidence of germ line mutations in the PTEN gene, which is located on the long arm of chromosome 10.

ManifestationThis section has been translated automatically.

Men and women are equally affected (Note: in contrast to autosomal recessive inheritance, men and women are equally affected even if they are heterozygous).

Clinical featuresThis section has been translated automatically.

Mutation analysis of the PTEN gene using direct DNA sequencing.

Characteristic features of Ruvalcaba-Myhre-Smith syndrome are

  • Birth weight of 4 kg and more (with high probability)
  • Birth height of 53 cm in girls (with high probability)
  • Birth height of 55 cm in boys (with high probability)
  • general development disruption/delay
  • Macrocephaly (in 50 % of those affected)
  • Hemangiomas (at 10 to 40)
  • multiple lipomas (at 75 %)
  • Melanotic spots (lentigines) on the penis (Freckling)
  • Macropenis (possible)
  • impaired motor function (at 50 %)
  • Muscle weakness (at 50 %)
  • Scoliosis (at 50 %)
  • Hemi-megalencephaly is less frequently detected (Ghusayni R et al. 2018)
  • Immunological dysregulations are possible (Eissing M et al.2019).

Complication(s)This section has been translated automatically.

With this genetic disposition there is an increased risk of developing thyroid cancer or intestinal carcinoma; women have a higher risk of developing breast cancer.

TherapyThis section has been translated automatically.

In individual cases therapy experiments with the immunosuppressive effective Sirolimus were made (Bevacqua M et al. 2019).

Note(s)This section has been translated automatically.

The Ruvalcaba-Myhre-Smith syndrome belongs to the group of hereditary hamartoma polyposis syndromes. These clinically overlapping syndromes involve mutations of the PTEN gene. Because of this clinical overlap, they are no longer strictly separated (Hereditary Hamartoma Polyposis Syndromes).

LiteratureThis section has been translated automatically.

  1. Bevacqua M et al (2019) Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature. Paediatric Drugs 21:185-193.
  2. Eissing M et al.(2019) PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. Transl Oncol 12:361-367.
  3. Golas MM et al(2019) Looking for the hidden mutation: Bannayan-Riley-Ruvalcaba syndrome caused by constitutional and mosaic 10q23 microdeletions involving PTEN and BMPR1A. At J Med Genet 179:1383-1389.
  4. Pilarski R et al (2019) PTEN Hamartoma Tumor Syndrome: A Clinical Overview. Cancers (Basel)11:6
  5. Ghusayni R et al (2018) Hemimegalencephaly with Bannayan-Riley-Ruvalcaba syndrome. Epileptic Disord. 2018 Feb 1;20(1):30-34.

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer